Analysis of p16 gene mutations and their expression using exhaled breath condensate in non‑small‑cell lung cancer
- Authors:
- Jin‑Liang Chen
- Jian‑Rong Chen
- Fen‑Fen Huang
- Guo‑Hua Tao
- Feng Zhou
- Yi‑Jiang Tao
View Affiliations
Affiliations: Department of Respiratory Medicine, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Biochemistry Laboratory, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
- Published online on: June 25, 2015 https://doi.org/10.3892/ol.2015.3426
-
Pages:
1477-1480
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present study was to investigate the mutational status of exons 1 and 2 of the p16 gene in the exhaled breath condensate (EBC) of patients with non‑small‑cell lung cancer (NSCLC) and determine the feasibility and clinical significance of applying EBC in the diagnosis of NSCLC. polymerase chain reaction and DNA sequencing were applied to detect exon 1 and 2 alterations of the p16 gene in EBC by comparing 58 samples from NSCLC patients and 30 from healthy controls. Of the 58 EBC samples from NSCLC patients, 54 were successfully tested and 8 cases of mutations were identified, of which 3 were in exon 1 and 5 in exon 2. The mutation rate was 14.81% (8/54). There were no p16 gene mutations in the 30 samples obtained from healthy controls. EBC p16 gene mutations exhibited no statistically significant differences according to gender, smoking history, pathological type, degree of differentiation and presence or absence of lymph node metastasis. The p16 gene mutation rate was proportional to the tumor stage (P<0.05). Therefore, the detection of the p16 gene mutation in EBC may be used as a novel molecular marker to assist in the diagnosis of NSCLC.
View References
|
1
|
Anglim PP, Alonzo TA and Laird-Offringa
IA: DNA methylation-based biomarkers for early detection of
non-small cell lung cancer: an update. Mol Cancer. 7:812008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pillai RN and Ramalingam SS: Advances in
the diagnosis and treatment of non-small cell lung cancer. Mol
Cancer Ther. 13:557–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koutsokera A, Loukides S, Gourgoulianis KI
and Kostikas K: Biomarkers in the exhaled breath condensate of
healthy adults: mapping the path towards reference values. Curr Med
Chem. 15:620–630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan HP, Lewis C and Thomas PS: Exhaled
breath analysis: novel approach for early detection of lung cancer.
Lung Cancer. 63:164–168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mozzoni P, Banda I, Goldoni M, et al:
Plasma and EBC microRNAs as early biomarkers of non-small-cell lung
cancer. Biomarkers. 18:679–686. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Padda SK, Burt BM, Trakul N and Wakelee
HA: Early-stage non-small cell lung cancer: surgery, stereotactic
radiosurgery, and individualized adjuvant therapy. Semin Oncol.
41:40–56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romagosa C, Simonetti S, López-Vicente L,
et al: p16(Ink4a) overexpression in cancer: a tumor suppressor gene
associated with senescence and high-grade tumors. Oncogene.
30:2087–2097. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carpagnano GE, Palladino GP, Gramiccioni
C, et al: New biomolecular methodologies in diagnosis of lung
cancer. Recenti Prog Med. 99:417–421. 2008.(In Italian). PubMed/NCBI
|
|
9
|
Gessner C, Kuhn H, Toepfer K, et al:
Detection of p53 gene mutations in exhaled breath condensate of
non-small cell lung cancer patients. Lung Cancer. 43:215–222. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiao P, Chen JR, Zhou F, et al:
Methylation of P16 in exhaled breath condensate for diagnosis of
non-small cell lung cancer. Lung Cancer. 83:56–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
